The effects of sesame, canola, and sesame–canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial

Amiri, Mojgan; Raeisi‐Dehkordi, Hamidreza; Moghtaderi, Fatemeh; Zimorovat, Alireza; Mohyadini, Matin; Salehi‐Abargouei, Amin

doi:10.1007/s00394-022-02898-9

Cited by 4 publications

(11 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present analysis was conducted on spouses who had no history of chronic diseases. The precise information about participants' characteristics and the study protocol is published elsewhere (Amiri et al, 2019)…”

Section: Methodsmentioning

confidence: 99%

“…It should be noted that we used the blended oil to check if it has a different beneficial effect on cardiometabolic markers. The detailed fatty acid composition of intervention oils is reported elsewhere (Amiri et al, 2019).…”

Section: Study Design and Interventionmentioning

confidence: 99%

“…Hence, all the participants, personnel, and statisticians were blinded to the treatment oils. Detailed methods used for randomization, allocation concealment, and blinding of participants and personnel are provided elsewhere (Amiri et al, 2019).…”

Section: Study Design and Interventionmentioning

confidence: 99%

“…The daily intake of foods and beverages was converted to grams/day and a computer-based program (Nutritionist IV software, version 3.5.2, Axxya Systems, Redmond, WA) was used for assessing the dietary intake. Physical activity records were converted to metabolic equivalent-min/day using standard methods (Amiri et al, 2019).…”

Section: Dietary Intake and Physical Activity Assessmentsmentioning

confidence: 99%

“…Investigators weighed intervention oil bottles before and after each phase to calculate the approximate amount of consumed oil. Moreover, 3-day weighed food records were evaluated to assess the consumed oils (Amiri et al, 2019).…”

Section: Treatment Compliancementioning

confidence: 99%

See 4 more Smart Citations

The effect of sesame, canola, and sesame‐canola oils on cardiometabolic risk factors in overweight adults: a three‐way randomized triple‐blind crossover clinical trial

Moghtaderi

Amiri

Raeisi‐Dehkordi

et al. 2022

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Limited data exist on the cardiometabolic effects of sesame oil compared with canola oil. In the present study, 77 overweight adults were randomized to replace their regularly consumed oils with canola (CO), sesame (SO), and sesame‐canola oils (SCO, 40% SO, and 60% CO) in three 9‐week phases. Blood pressure, visceral adiposity index, serum apo‐proteins (APOs) and lipid profile, glycemic control markers, kidney markers, liver enzymes, and cardiovascular disease risk scores were assessed at baseline and endline. After adjustment for confounders, SO significantly reduced serum alkaline aminotransferase (ALT) compared to CO (p ≤ 0.05) in all participants, increased serum urea compared to SCO in males, and decreased serum alkaline phosphatase compared to other oils in males, and improved serum high‐density lipoprotein cholesterol (HDL‐C) and triglycerides (TG) compared to SCO, and eGFR compared with CO in females (p ≤ 0.05). Canola oil significantly improved serum Apo A1 and APO B/A ratio compared with SO, in males (p ≤ 0.05). Sesame‐canola oil significantly reduced serum urea compared to other oils in all participants (p ≤ 0.05). Sesame oil and SCO might beneficially affect serum ALT and urea, respectively. Intervention oils might have different cardiometabolic effects in each gender. Further studies are needed to confirm our results (Trial registration code: IRCT2016091312571N6).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Design and Interventionmentioning

confidence: 99%

Section: Study Design and Interventionmentioning

confidence: 99%

Section: Dietary Intake and Physical Activity Assessmentsmentioning

confidence: 99%

Section: Treatment Compliancementioning

confidence: 99%

See 3 more Smart Citations

The effect of sesame, canola, and sesame‐canola oils on cardiometabolic risk factors in overweight adults: a three‐way randomized triple‐blind crossover clinical trial

Moghtaderi

Amiri

Raeisi‐Dehkordi

et al. 2022

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

Effect of sesame supplementation on body composition and lipid profile in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Vajdi,

Seyedhosseini-Ghaheh,

Hassanizadeh

et al. 2024

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

Vahedi

Atefi

Entezari

et al. 2022

Trials

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. There is strong evidence that dyslipidemia and other cardio-metabolic disorders are highly prevalent in patients with NAFLD. This trial aimed at examining the effect of sesame oil (SO) in the context of a weight loss program on lipid profile, blood pressure, and anthropometric indices in women with NAFLD. Methods This randomized, double-blind, controlled trial was carried out on 60 women with NAFLD. Subjects were randomly assigned to the SO group (n = 30) and sunflower oil (SFO) group (n = 30), each person consuming 30 g of oil per day for 12 weeks. All the participants received a hypocaloric diet (− 500 kcal/day) during the study. Lipid profile, blood pressure, and anthropometric indices were assessed at pre- and post-intervention phases. Results In total, 53 participants completed the study. Following 12 weeks of intervention, anthropometric indices (p < 0.001) and systolic blood pressure (SBP) (p < 0.05) were significantly decreased in both groups and diastolic blood pressure (DBP) was significantly decreased in So group (p = 0.03). There was no significant change in lipid profile in both groups (p > 0.05). After adjusting for confounders, DBP (p = 0.031) and total cholesterol (TC) divided by high-density lipoprotein cholesterol (HDL-C) (p = 0.039) in the SO group were significantly reduced compared to the SFO group (p < 0.05). Conclusions The present clinical trial revealed that SO and SFO may not differently affect anthropometric indices, SBP, and lipid profile except for TC/HDL-C. In addition, SO may be effective in improvement of DBP and TC/HDL-C compared to the SFO group. Trial registration Ethical approval of this trial was obtained at Isfahan University of Medical Sciences with the reference number of IR.MUI.RESEARCH.REC.1399.548 (https://ethics.research.ac.ir/ProposalCertificateEn.php?id=158942&Print=true&NoPrintHeader=true&NoPrintFooter=true&NoPrintPageBorder=true&LetterPrint=true), and it was registered before the start of the patient recruitment on December 12th, 2020 in the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20140208016529N6.

show abstract

The effects of sesame, canola, and sesame–canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial

Cited by 4 publications

References 77 publications

The effect of sesame, canola, and sesame‐canola oils on cardiometabolic risk factors in overweight adults: a three‐way randomized triple‐blind crossover clinical trial

The effect of sesame, canola, and sesame‐canola oils on cardiometabolic risk factors in overweight adults: a three‐way randomized triple‐blind crossover clinical trial

Effect of sesame supplementation on body composition and lipid profile in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial

Contact Info

Product

Resources

About